Lilly competitor claims early success with Alzheimer’s drug
Biogen Idec Inc. shares rose Tuesday after the company said its Alzheimer’s drug showed promising early results and will be quickly moved into a final-stage trial.
Health Care Businesses
Articles
Lilly in $440M osteoporosis patch deal with Zosano
Eli Lilly and Co. said Tuesday it will team up with Zosano Pharma Corp. on an experimental osteoporosis patch in a deal that could be worth more than $440 million.
Revenue has nearly tripled in past two years for blood-test maker
PTS Diagnostics engineered an about-face on its business plan five years ago, ditching its retail strategy to focus on serving physicians and nurse practitioners. This year, PTS is on pace to record revenue of nearly $50 million, up from $17 million two years ago.
Fifth person pleads guilty in Lilly warehouse heist
Prosecutors say the theft from an Eli Lilly and Co. warehouse in Connecticut involved up to $100 million in prescription drugs.
New type of cholesterol drug shows promise in study
The results have immediate implications for 1 million Americans who suffer mild heart attacks or chest pain each year. They may also make it easier for other experimental medicines from companies such as Eli Lilly to reach patients.
Two plead guilty in $50M Lilly prescription drug theft
Prosecutors said the two men and three others broke into a Lilly warehouse in March 2010 and stole thousands of boxes of drugs, including Zyprexa, Cymbalta, Prozac and Gemzar.
Research firm Covance to be acquired in $6.1 billion deal
Covance manages clinical trials for drugmakers including locally-based Eli Lilly and Co. It employs about 1,500 workers in Indianapolis and Greenfield.
Alzheimer’s drug makes Avanir potential Lilly target
Eli Lilly and Co. would be a logical acquirer for the maker of a drug that could treat agitation in Alzheimer’s patients.
Eli Lilly donates $12.7 million to United Way
The donation represents the giving of employees and retirees of Lilly and Elanco Animal Health in the U.S. and Puerto Rico, plus a matching contribution from the Lilly Foundation.
Central Indiana doctor faces prescription drug charges
Dr. Eric Jones of Pendleton was arrested Tuesday at his general family practice about 25 miles northeast of Indianapolis.
Takeda, Lilly win 99-percent cut in Actos damages award
Judge Rebecca Doherty in Lafayette, Louisiana, said the jury’s decision to order Takeda to pay $6 billion and Lilly $3 billion was excessive and should be reduced to a total of $36.8 million.
Seals Ambulance sells to Tennessee firm
Seals Ambulance, with 325 workers and nearly $13 million in revenue, will be acquired by Priority Ambulance, but keep its local leadership and name.
Lilly adds $375M to Zymeworks partnership
Eli Lilly and Co. and Zymeworks said Wednesday that they are expanding a cancer drug development partnership.
Zimmer profit beats forecasts, shares rise 4 percent
Shares of Warsaw-based orthopedic device maker Zimmer Holdings Inc. have doubled the performance of the S&P 500 so far this year.
Eli Lilly to sell Puerto Rico manufacturing facility
The Indianapolis company said it is closing its Guayama facility because the patents on some of the drugs made there have expired.
Lilly partner ordered to pay more than $2M to ex-Actos user
Takeda Pharmaceutical Co. was ordered by a jury to pay more than $2 million to a woman who claimed the company’s Actos diabetes medicine caused her bladder cancer, in the latest of thousands of lawsuits involving the drug to go to trial.
St. Vincent closure of Lafayette hospital to ax 83 jobs
St. Vincent Health will close its long-term acute hospital in Lafayette in the next two months, leaving as many as 83 workers without jobs. St. Vincent will continue to operate its other Seton Specialty Hospital in Indianapolis.
Lilly partner accused of putting Actos profit ahead of safety
Executives knew by 2004 that studies found links between Actos and cancer, and didn’t issue a warning until seven years later to protect billions of dollars in sales of the drug, attorney Michael Miller told a state-court jury in Philadelphia on Thursday.
European regulators OK Lilly’s $5.4B Novartis deal
The European Union's antitrust authority has approved the $5.4 billion sale of Novartis' animal health division to Indianapolis-based pharmaceutical firm Eli Lilly and Co.
Lilly to end development of lupus drug after trial failure
Tabalumab was expected to generate about $250 million to $300 million a year in sales in several years.